Form D · Other Technology
Liberation Bioindustries, Inc.
New York, NY · CIK 0001952448
Offering snapshot reported Dec 10, 2025 · SEC filing
- Reported sold
- $60.2M Offering amount: $102M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 10, 2025 | Initial | $60,164,351 | No comparison | 7 | SEC filing |
| Feb 10, 2025 | Initial | $51,982,971 | No comparison | 6 | SEC filing |
| Oct 28, 2022 | Initial | $9,100,009 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-566313
$56,664,354 of the Total Amount Sold was accounted for by the conversion of existing convertible notes. The remainder of the Total Amount Sold was accounted for by new cash investments.
Source: Form D, filed Dec 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Etan Bendheim | Executive |
| Philip Boigner | Director |
| Anthony Chow | Director |
| Steven Finn | Director |
| Babar Khan | Director |
| James Mellon | Director |
| Mark Warner | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
14 Wall Street 20th Floor
New York, NY, 10005
New York, NY, 10005